MA-IBASIS
29.6.2021 08:02:06 CEST | Business Wire | Press release
iBASIS , the leading provider of communications solutions for operators and digital players worldwide, announced it will partner with SIPPIO , the largest, secure, Azure-based provider of voice-calling services for Microsoft Teams, globally. The relationship enables both companies to address the fast-growing global demand for unified communications and collaboration services with Cloud Numbering and International Voice Termination.
The seismic shift to all cloud-based communication platforms is exemplified by Microsoft Teams’ 145 million daily active users. As recently reported by Synergy Group Research , “Microsoft has become the second-largest Unified Communications-as-a-Service (UCaaS) provider in the world.” As usage increases, so does the demand for exponentially growing voice calling services.
iBASIS and SIPPIO are responding to this demand with iBASIS’ expansion of Cloud Numbering and International Voice Termination combined with SIPPIO’s fully automated, end-to-end cloud solution platform, delivering top-grade communications and carrier services and leveraging automation to eliminate the cost, complexity, and time of building direct routing as a ‘one-off.’ This ensures both reliability and redundancy on a global scale with the highest levels of security, compliance, and data privacy.
iBASIS provides SIPPIO with enhanced coverage in various hard-to-reach destinations across the globe. Recent examples of iBASIS’ strengths in addressing demand from key geographies include iBASIS’ partnership with China Telecom Europe , which enabled CTE to achieve instant traction by leveraging iBASIS Carrier Voice for Teamwork™ to provide European multinationals with full calling capabilities to their collaboration platforms.
“SIPPIO is an innovative cloud solution player forging new capabilities and commercialization opportunities for fully automated, cloud-based direct routing as a service,” says Edwin van Ierland , Chief Commercial Officer and Chief Operating Officer at iBASIS. “This relationship showcases how iBASIS’ Carrier Cloud Communications portfolio , global reach, scale, and independence are critical to the global requirements for cloud communications.”
“This is a pivotal moment in which the demand to shift voice calling to the same world as online meetings is a major market driver,” adds Dawn-Marie Elder, COO, SIPPIO. “Partnering with iBASIS extends SIPPIO’s global footprint, reinforcing our ability to provide operators with the highest quality, tier-1 voice capabilities and fastest time to market to bring these solutions to their enterprise customers.”
iBASIS Carrier Voice for Teamwork is part of iBASIS’ larger Carrier Cloud Communications portfolio that includes cloud numbering solutions, international numbers, global voice termination, and Communications Platform as a Service (CPaaS). iBASIS’ carrier-grade API marketplace includes a full CPaaS suite to meet the growing and urgent need for collaborative tools and applications – including solutions for iBASIS Carrier Voice for Teamwork™ , two-factor authentication, live support, and contact center services.
SIPPIO empowers channel partners and carriers with capabilities to capitalize on the demand for voice-enabled collaboration platforms like Microsoft Teams. By minimizing resource consumption from end to end, SIPPIO expands the universe of potential customers for partners, making it economically viable to pursue smaller companies as well as Fortune 500 enterprises.
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.
About SIPPIO
Headquartered in Annapolis, MD, SIPPIO is the largest platform provider to enable voice in Microsoft Teams. As a Co-Sell Preferred partner, SIPPIO provides partners and carriers with a fully automated, Azure native, end-to-end solution. Available globally with toll-free and emergency services, SIPPIO does not require any code, build, or maintenance. SIPPIO activates full calling capabilities in minutes and scales with business needs to enhance communications and collaboration to unify the modern workplace experience. Visit www.sippio.io for additional information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005768/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom